Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/26/2025

Adjusting Tresiba for Optimal Glycemic Control

Initial Dosing Strategy

  • The American College of Cardiology recommends starting Tresiba at 0.1-0.2 units/kg/day for standard hyperglycemia, with a total daily insulin dose of 0.4-1.0 units/kg/day, approximately 50% as basal insulin, for type 1 diabetes patients 1, 3
  • For type 2 diabetes patients with severe hyperglycemia, consider starting with 0.3-0.4 units/kg/day or an immediate basal-bolus regimen, and continue metformin unless contraindicated 1, 2

Evidence-Based Titration Algorithm

  • Increase Tresiba by 2 units every 3-4 days if fasting glucose is 140-179 mg/dL, or by 4 units every 3-4 days if fasting glucose ≥180 mg/dL, until reaching a target of 80-130 mg/dL 1, 3
  • Maintain current dose if fasting glucose is 80-130 mg/dL, decrease by 2 units if more than 2 fasting values per week are <80 mg/dL, and reduce dose by 10-20% immediately if hypoglycemia occurs 1, 3

Critical Threshold: When to Stop Escalating Basal Insulin

  • When Tresiba exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, add prandial insulin rather than continuing to escalate basal insulin alone, as recommended by the American Diabetes Association 1, 3

Adding Prandial Insulin

  • Start with 4 units of rapid-acting insulin before the largest meal, or use 10% of current basal dose as initial prandial dose, and increase prandial insulin by 1-2 units or 10-15% every 3 days based on postprandial glucose 1, 3

Special Populations and Situations

  • For hospitalized patients, use 0.3-0.5 units/kg/day total, with half as basal, and reduce total daily dose by 20% to prevent hypoglycemia for patients on high-dose home insulin 1
  • When adding SGLT2 inhibitors, reduce total daily insulin by approximately 20% to prevent euglycemic ketoacidosis, as recommended by the Journal of the American College of Cardiology 4
  • When adding GLP-1 receptor agonists, consider as alternative to prandial insulin intensification, and reduce dose by 50% or discontinue sulfonylureas when intensifying insulin 1, 3, 4